NEW YORK, NY / ACCESSWIRE / May 6, 2015 / Market Exclusive announces that Zacks Small-Cap Research has upgraded Aethlon Medical (AEMDD) to a Buy rating with a 12-month price target of $18.00 per share.
Outlining Aethlon's operational update, Zacks analyst Brian Marckx, CFA writes, "It has been a busy few months for Aethlon which has culminated in progress on several fronts towards further research and validation of Hemopurifier in various applications…In addition to meaningful progress with Hemopurifier, Exosome Sciences, AEMD's subsidiary focused on exosome-related diagnostic products, continues to forge ahead with research related to CTE and cancer diagnostics."
About Market Exclusive
Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive